Advertisement

Topics

Biogen Spooks With Phase III Aducanumab Changes

07:06 EST 15 Feb 2018 | SCRIP

Recruiting more patients into a trial to retain statistical power is standard practice, but with other companies discontinuing late-stage investigational...

      

Related Stories

 

Original Article: Biogen Spooks With Phase III Aducanumab Changes

NEXT ARTICLE

More From BioPortfolio on "Biogen Spooks With Phase III Aducanumab Changes"

Advertisement
Quick Search
Advertisement
Advertisement